While the discussion on the appropriateness of PSA (and PCA3) screening is still open, it is widely held that improved biomarkers, especially biomarkers that distinguish normal prostate tissue from prostate cancer and markers associated with aggressive disease, could greatly improve prostate cancer screening results and deliver the benefit of early diagnosis and appropriate treatment to many men. Here, PCA3 is linked to prostate carcinoma.